ZILBRYSQ
Dead / Abandoned — Abandoned — no statement of use filed (as of 23 Oct 2023)
What this means for you
This application is over — abandoned 23 Oct 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88850346
- Mark type
- Stylized text
- Filed
- 27 Mar 2020
- Published for opposition
- 28 Jul 2020
- Abandoned
- 23 Oct 2023
- Attorney of record
- Kumiko Ide
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, for human use, for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, myasthenia gravis, an inflammatory disorder, a wound, a burn, an autoimmune disorder, a pulmonary disorder, a cardiovascular disorder, a neurological disorder, a kidney-related disorder, a diabetes-related disorder, an ocular disorder, and a pregnancy-related disorder; Pharmaceutical preparations, for human use, for the prevention and treatment of disorders of metabolism, the nervous system, the immune system, the cardio-vascular system, the respiratory system, the musculo-skeletal system, and the genitourinary system; Pharmaceutical preparations for the treatment of fibrotic and inflammatory disorders; Pharmaceutical preparations for use in dermatology, nephrology, hepatology, rheumatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations as anti-viral, anti-bacterial, or anti-fungal agents
- Class 010 — Medical apparatus: Syringes for injections; Syringes for medical purposes; Syringes for medical purposes sold empty which may be filled with pharmaceutical preparations, for human use, for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, myasthenia gravis, an inflammatory indication, a wound, a burn, an autoimmune indication, a pulmonary indication, a cardiovascular indication, a neurological indication, a kidney-related indication, a diabetes-related indication, an ocular indication, and a pregnancy-related indication
Owner
- Ra Pharmaceuticals, Inc., Cambridge, MA, US
- Ra Pharmaceuticals, Inc., Cambridge, MA, US
Prosecution history
- 23 Oct 2023 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 23 Oct 2023 — ABANDONMENT - NO USE STATEMENT FILED
- 22 Mar 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 21 Mar 2023 — SOU EXTENSION 5 GRANTED
- 08 Mar 2023 — SOU EXTENSION 5 FILED
- 21 Mar 2023 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 08 Mar 2023 — SOU TEAS EXTENSION RECEIVED
- 02 Sept 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 31 Aug 2022 — SOU EXTENSION 4 GRANTED
- 31 Aug 2022 — SOU EXTENSION 4 FILED
- 31 Aug 2022 — SOU TEAS EXTENSION RECEIVED
- 08 Mar 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Mar 2022 — SOU EXTENSION 3 GRANTED
- 04 Mar 2022 — SOU EXTENSION 3 FILED
- 04 Mar 2022 — SOU TEAS EXTENSION RECEIVED